Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Guselkumab and Ustekinumab in Healthy Chinese Subjects
NCT04030533Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2019
- Primary completion
- Dec 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of guselkumab in plaque psoriasis (5 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Serum Concentration at Day 85, Area Under the Serum Concentration-Time Curve at Day 85 and 5 more. Started Nov 2019; status: completed.
02
Drugs
guselkumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04030533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04030533.